First reported case of concurrent sonidegib and radiotherapy for recurrent, advanced basal cell carcinoma

Rep Pract Oncol Radiother. 2021 Feb 25;26(1):149-152. doi: 10.5603/RPOR.a2021.0010. eCollection 2021.


Basal cell carcinoma (BCC ) is the most common human malignancy. Systemic therapy with a sonic hedgehog (SHH) pathway inhibitor plays an important role in the treatment of advanced BCC . Literature on concurrent use of radiation therapy (RT ) with SHH inhibitors has been minimal and has solely been focused on vismodegib. We present a case report of a patient with recurrent basal cell carcinoma involving the high-risk area of the face, who was denied surgery due to comorbidities and difficulty in obtaining complete tumor removal without cosmetic or functional impairment. The patient received combined treatment of fractionated radiation with concurrent sonidegib and had complete clinical response with no significant toxicities. This is the first reported case on the use of concurrent RT with sonidegib for management of recurrent basal cell carcinoma of the head and neck.

Keywords: basal cell carcinoma; concurrent radiotherapy; radiation oncology; sonic hedgehog; systemic therapy.

Publication types

  • Case Reports